Harnessing the tumor-tropic capacity of MSCs, Li et al. [130] and Ciavarella et al. [109] demonstrated the killing capacity of MSC towards leukemia and myeloma cells after engineering them for the expression of human interferon-gamma (IFN-γ) and TRAIL, respectively. This evidence concerns the gene IFNG and leukemia.